source
- Minghui Pharma sells Japanese rights to its Phase 3 thyroid eye disease drug for $110 million upfrontMinghui Pharmaceutical, a Shanghai‑based biotech, has agreed to transfer the Japanese commercial rights for its late‑stage thyroid eye disease candidate to a specialty pharmaceutical company. The…
- Spyre Therapeutics reports SPY072 fails psoriatic arthritis trial as Ideaya halts eye cancer studySpyre Therapeutics announced that its long‑acting anti‑TL1A candidate, SPY072, did not meet the primary endpoints in a psoriatic arthritis trial. The result adds to recent setbacks for Spyre in ot…